Results 21 to 30 of about 355,945 (323)
Specific lid-base contacts in the 26s proteasome control the conformational switching required for substrate degradation. [PDF]
The 26S proteasome is essential for proteostasis and the regulation of vital processes through ATP-dependent degradation of ubiquitinated substrates. To accomplish the multi-step degradation process, the proteasomes regulatory particle, consisting of lid
Aufderheide +42 more
core +1 more source
The ubiquitin‐proteasome pathway and proteasome inhibitors [PDF]
AbstractThe ubiquitin‐proteasome pathway has emerged as a central player in the regulation of several diverse cellular processes. Here, we describe the important components of this complex biochemical machinery as well as several important cellular substrates targeted by this pathway and examples of human diseases resulting from defects in various ...
J, Myung, K B, Kim, C M, Crews
openaire +2 more sources
ATM deficiency results in accumulation of DNA-Topoisomerase I covalent intermediates in neural cells [PDF]
Accumulation of peptide-linked DNA breaks contributes to neurodegeration in humans. This is typified by defects in tyrosyl DNA phosphodiesterase 1 (TDP1) and human hereditary ataxia.
Alagoz, Meryem +3 more
core +6 more sources
The proteasome is a multi-catalytic molecular machine that plays a key role in the degradation of many cytoplasmic and nuclear proteins. The proteasome is essential and proteasome malfunction is associated with various disease pathologies.
Sabine Schipper-Krom +6 more
doaj +1 more source
Assembly and disassembly of branched ubiquitin chains
Protein ubiquitylation is an essential post-translational modification that regulates nearly all aspects of eukaryotic cell biology. A diverse collection of ubiquitylation signals, including an extensive repertoire of polymeric ubiquitin chains, leads to
Justin B. Gregor +3 more
doaj +1 more source
Broad activation of the ubiquitin-proteasome system by Parkin is critical for mitophagy [PDF]
Parkin, an E3 ubiquitin ligase implicated in Parkinson's disease, promotes degradation of dysfunctional mitochondria by autophagy. Using proteomic and cellular approaches, we show that upon translocation to mitochondria, Parkin activates the ubiquitin ...
Anh H. Pham +49 more
core +3 more sources
Proteasome inhibitors have a 20 year history in cancer therapy. The first proteasome inhibitor, bortezomib (Velcade, PS-341), a break-through multiple myeloma treatment, moved rapidly through development from bench in 1994 to first approval in 2003. Bortezomib is a reversible boronic acid inhibitor of the chymotrypsin-like activity of the proteasome ...
Teicher, Beverly A. +1 more
openaire +2 more sources
Rethinking Proteasome Evolution: Two Novel Bacterial Proteasomes [PDF]
The proteasome is a multisubunit structure that degrades proteins. Protein degradation is an essential component of regulation because proteins can become misfolded, damaged, or unnecessary. Proteasomes and their homologues vary greatly in complexity: from HslV (heat shock locus v), which is encoded by 1 gene in bacteria, to the eukaryotic 20S ...
Valas, Ruben E., Bourne, Philip E.
openaire +2 more sources
Pharmacological strategies in lung cancer-induced cachexia: effects on muscle proteolysis, autophagy, structure, and weakness [PDF]
Muscle wasting and cachexia are important systemic manifestations of highly prevalent conditions including cancer. Inflammation, oxidative stress, autophagy, ubiquitin-proteasome system, nuclear factor (NF)-kB, and mitogen activated protein kinases (MAPK)
Bal, Elisa Dora +7 more
core +1 more source
The capture proteasome assay (CAPA) to evaluate subtype-specific proteasome inhibitors
We recently developed a new assay to measure proteasome activity in vitro (CAPA for capture proteasome assay) [1], based on proteasome capture on an antibody-coated plate.
Nathalie Vigneron +2 more
doaj +1 more source

